Valbiotis SA Reports Strong First-Half 2026 Growth

Valbiotis SA has announced promising results for the first half of 2026. Revenue reached €0.8 million, reflecting a 130% increase compared to the same period last year. This growth was driven by an increase in the number of customers and higher average basket sizes through both pharmacies and e-commerce platforms.

The company's cash position was bolstered to €11.7 million, ensuring operations through 2027. While operating expenses rose moderately by 8% to €5.5 million, reflective of strengthened sales efforts, general and administrative costs saw a notable increase of 70% due to non-recurring structuring expenses.

Valbiotis noted a significant reduction in research and development costs, signifying a shift towards commercial expansion. Despite a net loss of €3.4 million, the company's strategic direction aims to enhance its position in the cardiometabolic sector internationally, leveraging key agreements for future growth.